$5.51
-0.02-0.36%
Last update: Oct 13, 4:00 PM
$5.53
N/A

Aligos Therapeutics (ALGS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.28 | $-2.29 | $-2.33 | $-2.04 |
| Actual | $-0.14 | $-2.21 | $-1.91 | $-3.04 |
| Surprise | +89.1% | +3.49% | +18.0% | -49.0% |
| Revenue | ||||
| Estimate | $18.9M | $333330 | $266670 | $500000 |
| Actual | $0 | $2.8M | $169000 | $741000 |
| Surprise | -100.0% | +749.0% | -36.6% | +48.2% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-2.51 | $-1.76 | $-1.64 | $-1.64 |
| Revenue | ||||
| Consensus | $5.0M | $614290 | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.14 | $-1.28 | 89.1 % |
| Q1 | May 7, 2026 | $-2.21 | $-2.29 | 3.49 % |
| Q4 | Mar 5, 2026 | $-1.91 | $-2.33 | 18.0 % |
| Q3 | Nov 6, 2025 | $-3.04 | $-2.04 | -49.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $0 | $18.88M | -100.0 % |
| Q1 | May 7, 2026 | $2.83M | $333.33K | 749.0 % |
| Q4 | Mar 5, 2026 | $169.00K | $266.67K | -36.6 % |
| Q3 | Nov 6, 2025 | $741.00K | $500.00K | 48.2 % |